|
293 Companies |
|
491 Products |
|
491 Products |
|
198 Mechanisms of Action |
|
26 Trials |
|
7806 News |
|
| «12345678910111213...156157» |
- | Tysabri (natalizumab) / Biogen, Royalty
Phase classification: CogMS: Cognitive Evolution in Tysabri Treated Multiple Sclerosis Patients (clinicaltrials.gov) - Mar 6, 2019
P=N/A, N=63, Completed, Sponsor: Clinique Neuro-Outaouais
Phase classification: P4 --> P=N/A
- | Trial completion, Trial completion date, Trial primary completion date: Pilot Study of Between Visit Interaction to Improve Glycemic Control in Pregnancy With Pre-existing Diabetes (clinicaltrials.gov) - Mar 6, 2019
P=N/A, N=12, Completed, Sponsor: Mayo Clinic
Phase classification: P4 --> P=N/A Recruiting --> Completed | Trial completion date: May 2016 --> Jan 2019 | Trial primary completion date: May 2016 --> Jan 2019
- | Trial completion, Trial completion date: Reverse Transcriptase Inhibitors in AGS (clinicaltrials.gov) - Mar 5, 2019
P2, N=11, Completed, Sponsor: Assistance Publique - H
Recruiting --> Completed | Trial completion date: May 2016 --> Jan 2019 | Trial primary completion date: May 2016 --> Jan 2019 Active, not recruiting --> Completed | Trial completion date: Jan 2018 --> Jun 2018
- | Trial completion, Trial completion date, Trial primary completion date: Mindfulness-based Stress Reduction in Multiple Sclerosis (clinicaltrials.gov) - Mar 1, 2019
P=N/A, N=50, Completed, Sponsor: NHS Greater Glasgow and Clyde
Active, not recruiting --> Completed | Trial completion date: Jan 2018 --> Jun 2018 Recruiting --> Completed | Trial completion date: Aug 2015 --> Aug 2016 | Trial primary completion date: Aug 2015 --> Aug 2016
- | Trial completion: "MS-Fit": Standardized Ambulatory Neurorehabilitation Program for Patients With Multiple Sclerosis (clinicaltrials.gov) - Mar 1, 2019
P=N/A, N=65, Completed, Sponsor: University Hospital Inselspital, Berne
Recruiting --> Completed | Trial completion date: Aug 2015 --> Aug 2016 | Trial primary completion date: Aug 2015 --> Aug 2016 Active, not recruiting --> Completed
- | Trial completion, Trial completion date: Adipose Tissue Function After Pancreas Transplantation (clinicaltrials.gov) - Mar 1, 2019
P=N/A, N=15, Completed, Sponsor: The University of Texas Medical Branch, Galveston
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Jan 2018 --> Feb 2019
- | Benlysta (belimumab) / GSK, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial completion, Trial completion date, Trial primary completion date: SYNBIoSe: Synergetic B-cell Immodulation in SLE (clinicaltrials.gov) - Feb 28, 2019
P2, N=16, Completed, Sponsor: Leiden University Medical Center
Active, not recruiting --> Completed | Trial completion date: Jan 2018 --> Feb 2019 Recruiting --> Completed | Trial completion date: Mar 2020 --> Oct 2018 | Trial primary completion date: Mar 2018 --> Oct 2018
- || Enbrel (etanercept) / Pfizer, Amgen
Trial completion: TARGET-DLE: Targeted Therapy Using Intradermal Injection of Etanercept for Remission Induction in Discoid Lupus Erythematosus (clinicaltrials.gov) - Feb 27, 2019
P2, N=25, Completed, Sponsor: University of Leeds
Recruiting --> Completed | Trial completion date: Mar 2020 --> Oct 2018 | Trial primary completion date: Mar 2018 --> Oct 2018 Active, not recruiting --> Completed
- | Byetta (exenatide) / AstraZeneca
Phase classification, Enrollment change: Role of Exenatide in Type 1 Diabetes (clinicaltrials.gov) - Feb 26, 2019
P2, N=11, Completed, Sponsor: Montefiore Medical Center
Active, not recruiting --> Completed Phase classification: P4 --> P2 | N=17 --> 11
- | zoledronic acid / Generic mfg.
Enrollment change, Trial completion date, Trial termination: AZAR: Zoledronic Acid in Rheumatoid Arthritis (clinicaltrials.gov) - Feb 22, 2019
P3, N=28, Terminated, Sponsor: Carmen Gómez-Vaquero
Phase classification: P4 --> P2 | N=17 --> 11 N=94 --> 28 | Trial completion date: Dec 2018 --> Jun 2018 | Recruiting --> Terminated
- ||| Actemra SC (tocilizumab SC) / Roche, Halozyme
Trial completion, Combination therapy, Monotherapy: EMBRACE-SC: Observational Study of Subcutaneous (SC) Tocilizumab Alone or in Combination With Conventional Disease-Modifying Antirheumatic Drugs (cDMARDs) in Rheumatoid Arthritis (clinicaltrials.gov) - Feb 22, 2019
P=N/A, N=200, Completed, Sponsor: Hoffmann-La Roche
N=94 --> 28 | Trial completion date: Dec 2018 --> Jun 2018 | Recruiting --> Terminated Active, not recruiting --> Completed
- | Trial completion, Trial completion date, Trial primary completion date: New Treatment for Patients With Temporal Hollowing After Lateral Wall Decompression (clinicaltrials.gov) - Feb 22, 2019
P=N/A, N=29, Completed, Sponsor: Haukeland University Hospital
Active, not recruiting --> Completed Enrolling by invitation --> Completed | Trial completion date: Jan 2021 --> May 2018 | Trial primary completion date: Dec 2018 --> Jan 2018
- | Trial completion: GADD34-LES: Prognosis Assessment of the Increase of GADD34 Gene Expression for Patient Suffering From Systemic Lupus Erythematosus (clinicaltrials.gov) - Feb 21, 2019
P=N/A, N=143, Completed, Sponsor: University Hospital, Grenoble
Enrolling by invitation --> Completed | Trial completion date: Jan 2021 --> May 2018 | Trial primary completion date: Dec 2018 --> Jan 2018 Active, not recruiting --> Completed
- | Trial completion: Mitochondrial Dysfunction and Disease Progression (clinicaltrials.gov) - Feb 20, 2019
P=N/A, N=47, Completed, Sponsor: Icahn School of Medicine at Mount Sinai
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Enrollment closed: "MS-Fit": Standardized Ambulatory Neurorehabilitation Program for Patients With Multiple Sclerosis (clinicaltrials.gov) - Feb 19, 2019
P=N/A, N=65, Active, not recruiting, Sponsor: University Hospital Inselspital, Berne
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||| Trial completion: How Does Strength Training and Balance Training Affect Gait Function and Fatigue in Patients With Multiple Sclerosis? (clinicaltrials.gov) - Feb 19, 2019
P=N/A, N=71, Completed, Sponsor: University of Aarhus
Recruiting --> Active, not recruiting Recruiting --> Completed
- | Proleukin (aldesleukin) / Novartis, Prometheus, Iovance Biotherap
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: ANEMIL: Evaluating the Interest of Interleukine-2 for Patients With Active Warm Hemolytic Anemia Resistant to Conventional Treatment (clinicaltrials.gov) - Feb 18, 2019
P1/2, N=2, Completed, Sponsor: University Hospital, Bordeaux
Recruiting --> Completed Recruiting --> Completed | N=10 --> 2 | Trial completion date: Dec 2019 --> Nov 2018 | Trial primary completion date: Dec 2019 --> Nov 2018
- | Victoza (liraglutide) / Novo Nordisk
Enrollment change, Trial withdrawal: DIAB-01: Vitamin C and Liraglutide Effects on Hypoglycemia-induced Oxidative Stress, Inflammation and Endothelial Dysfunction in Type 1 Diabetes. (clinicaltrials.gov) - Feb 15, 2019
P1, N=0, Withdrawn, Sponsor: Anna Cruceta
Recruiting --> Completed | N=10 --> 2 | Trial completion date: Dec 2019 --> Nov 2018 | Trial primary completion date: Dec 2019 --> Nov 2018 N=20 --> 0 | Not yet recruiting --> Withdrawn
- | dalfampridine / Generic mfg.
Trial completion, HEOR: FAMILY: Fampridine in MS Patients: A Cognition, Fatigue, Depression and Quality of Life Analysis (clinicaltrials.gov) - Feb 15, 2019
P=N/A, N=111, Completed, Sponsor: Genesis Pharma CNS & Specialty
N=20 --> 0 | Not yet recruiting --> Withdrawn Active, not recruiting --> Completed
- ||| Tysabri (natalizumab) / Biogen, Royalty
Trial completion: STRIVE: Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JC Virus Antibody Negative Participants (clinicaltrials.gov) - Feb 12, 2019
P=N/A, N=231, Completed, Sponsor: Biogen
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion: Closed-loop Control of Glucose Levels (Artificial Pancreas) During Postprandial Exercise in Adults With Type 1 Diabetes (clinicaltrials.gov) - Feb 11, 2019
P2, N=37, Completed, Sponsor: Institut de Recherches Cliniques de Montreal
Active, not recruiting --> Completed Recruiting --> Completed
- | Leukine (sargramostim) / Partner Therap
Trial completion: Pulmonary Alveolar Proteinosis GM-CSF Inhalation Efficacy Trial in Japan (clinicaltrials.gov) - Feb 7, 2019
P2, N=78, Completed, Sponsor: Niigata University Medical & Dental Hospital
Recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion, Enrollment change: Feasibility and Reliability of Multimodal Evoked Potentials in an International Multicenter Setting (clinicaltrials.gov) - Feb 6, 2019
P=N/A, N=14, Completed, Sponsor: Clinique Neuro-Outaouais
Active, not recruiting --> Completed Recruiting --> Completed | N=10 --> 14
- | Trial completion, Trial completion date, Trial primary completion date: EMOSOCIAL-MS: Emotional Processing, Family Life, Friendship and Social Integration in Patients With Multiple Sclerosis (clinicaltrials.gov) - Feb 5, 2019
P=N/A, N=91, Completed, Sponsor: University Hospital, Bordeaux
Recruiting --> Completed | N=10 --> 14 Recruiting --> Completed | Trial completion date: Sep 2018 --> Jan 2019 | Trial primary completion date: Sep 2018 --> Jan 2019
- ||| Trial completion, Trial completion date, Trial primary completion date: APRAN: Assessment of Tender & Swollen Joints Count Score Performed by a Rheumatologist And Rheumatology Nurses in Patients With RA and PsA. (clinicaltrials.gov) - Feb 1, 2019
P=N/A, N=80, Completed, Sponsor: Isabelle Fortin
Recruiting --> Completed | Trial completion date: Sep 2018 --> Jan 2019 | Trial primary completion date: Sep 2018 --> Jan 2019 Recruiting --> Completed | Trial completion date: Sep 2019 --> Nov 2018 | Trial primary completion date: Mar 2019 --> Nov 2018
- | Trial completion, Enrollment change, Trial completion date: Psychosocial Functioning in Young Adults With Type 1 Diabetes (clinicaltrials.gov) - Feb 1, 2019
P=N/A, N=47, Completed, Sponsor: Children's Hospital Medical Center, Cincinnati
Recruiting --> Completed | Trial completion date: Sep 2019 --> Nov 2018 | Trial primary completion date: Mar 2019 --> Nov 2018 Active, not recruiting --> Completed | N=120 --> 47 | Trial completion date: Sep 2018 --> Dec 2018
- | Trial completion: Diabeloop WP7 : Crossover Evaluation of the Safety and the Efficacy of Artificial Pancreas Diabeloop (WP7) (clinicaltrials.gov) - Feb 1, 2019
P=N/A, N=71, Completed, Sponsor: Centre d
Active, not recruiting --> Completed | N=120 --> 47 | Trial completion date: Sep 2018 --> Dec 2018 Active, not recruiting --> Completed
- | Trial completion: Dissemination of the Lupus Interactive Navigator (clinicaltrials.gov) - Jan 31, 2019
P=N/A, N=541, Completed, Sponsor: CHU de Quebec-Universite Laval
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion, Trial completion date: Vestibular Rehabilitation for Persons With Multiple Sclerosis: Who Benefits the Most? (MSVR3trial) (clinicaltrials.gov) - Jan 29, 2019
P=N/A, N=88, Completed, Sponsor: University of Colorado, Denver
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Nov 2018 --> Aug 2018
- | Trial completion, Trial completion date, Trial primary completion date: BIOSAFE: Efficiency of a Nurse-led Self-management Education Intervention in Promoting Safety Knowledge and Skills of Patients With Arthritis Treated Par Biologics (clinicaltrials.gov) - Jan 28, 2019
P=N/A, N=129, Completed, Sponsor: Assistance Publique - Hôpitaux de Paris
Active, not recruiting --> Completed | Trial completion date: Nov 2018 --> Aug 2018 Recruiting --> Completed | Trial completion date: Mar 2018 --> Nov 2018 | Trial primary completion date: Mar 2018 --> Nov 2018
- || Myasterix (CV-MG01) / CuraVac
Trial completion, Trial completion date, Trial primary completion date: Safety, Tolerability and Immunogenic Response of CV-MG01 in Patients With Myasthenia Gravis (clinicaltrials.gov) - Jan 28, 2019
P1/2, N=24, Completed, Sponsor: CuraVac
Recruiting --> Completed | Trial completion date: Mar 2018 --> Nov 2018 | Trial primary completion date: Mar 2018 --> Nov 2018 Active, not recruiting --> Completed | Trial completion date: Nov 2019 --> Sep 2018 | Trial primary completion date: Sep 2019 --> Sep 2018
- || elcubragistat (Lu AG06466) / Lundbeck
Trial completion, Enrollment change: Central Pain Study for ABX-1431 (clinicaltrials.gov) - Jan 25, 2019
P1, N=9, Completed, Sponsor: Abide Therapeutics
Active, not recruiting --> Completed | Trial completion date: Nov 2019 --> Sep 2018 | Trial primary completion date: Sep 2019 --> Sep 2018 Active, not recruiting --> Completed | N=32 --> 9
- | Trial completion, Enrollment change: CADI: Creative Arts Diabetes Initiative for Youth/Young Adults Transitioning to Adult Care (clinicaltrials.gov) - Jan 23, 2019
P=N/A, N=12, Completed, Sponsor: University of Manitoba
Active, not recruiting --> Completed | N=32 --> 9 Recruiting --> Completed | N=20 --> 12
- || Orencia (abatacept) / BMS
Trial completion date, Trial primary completion date: Safety Study of Abatacept to Treat Rheumatoid Arthritis (B) (clinicaltrials.gov) - Jan 19, 2019
P=N/A, N=20000, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Recruiting --> Completed | N=20 --> 12 Trial completion date: Oct 2019 --> Jun 2029 | Trial primary completion date: Oct 2019 --> Jun 2029
- | Trial completion, Immunomodulating: Helminth-induced Immunomodulation Therapy (HINT) in Relapsing-remitting Multiple Sclerosis (clinicaltrials.gov) - Jan 16, 2019
P1, N=17, Completed, Sponsor: University of Wisconsin, Madison
Trial completion date: Oct 2019 --> Jun 2029 | Trial primary completion date: Oct 2019 --> Jun 2029 Active, not recruiting --> Completed
- | Trial completion: Insulin Management for Exercise in Patients With Type 1 Diabetes (clinicaltrials.gov) - Jan 15, 2019
P=N/A, N=17, Completed, Sponsor: York University
Active, not recruiting --> Completed Recruiting --> Completed
- | Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Discordant: DIAPO: Discrepancies Between Patients and Physicians in Their Perceptions of Rheumatoid Arthritis Disease Activity (clinicaltrials.gov) - Jan 14, 2019
P=N/A, N=79, Active, not recruiting, Sponsor: Centre Hospitalier Universitaire de Nīmes
Recruiting --> Completed Recruiting --> Active, not recruiting | N=200 --> 79 | Trial completion date: Mar 2018 --> Mar 2019 | Trial primary completion date: Mar 2018 --> Mar 2019
- | Trial completion, Trial completion date, Trial primary completion date: SAMSPAP: Sleep Apnea in Multiple Sclerosis Positive Airway Pressure Trial (clinicaltrials.gov) - Jan 12, 2019
P=N/A, N=49, Completed, Sponsor: McGill University
Recruiting --> Active, not recruiting | N=200 --> 79 | Trial completion date: Mar 2018 --> Mar 2019 | Trial primary completion date: Mar 2018 --> Mar 2019 Recruiting --> Completed | Trial completion date: Mar 2019 --> Nov 2018 | Trial primary completion date: Sep 2018 --> Nov 2018
- | Trial completion, Trial completion date: Douleur-PR: Pain Evaluation in Rheumatoid Arthritis (clinicaltrials.gov) - Jan 12, 2019
P=N/A, N=300, Completed, Sponsor: University Hospital, Limoges
Recruiting --> Completed | Trial completion date: Mar 2019 --> Nov 2018 | Trial primary completion date: Sep 2018 --> Nov 2018 Active, not recruiting --> Completed | Trial completion date: Sep 2015 --> Dec 2017
- | Trial completion, Enrollment change, Trial completion date: Do Inflammatory Arthritis Inpatients Receiving Group Music Therapy Improve Pain Compared to Music Listening? (clinicaltrials.gov) - Jan 11, 2019
P=N/A, N=13, Completed, Sponsor: University of British Columbia
Active, not recruiting --> Completed | Trial completion date: Sep 2015 --> Dec 2017 Active, not recruiting --> Completed | N=20 --> 13 | Trial completion date: Jun 2019 --> Jan 2018
- | Trial completion: NeuroSenSS: Primary Sj (clinicaltrials.gov) - Jan 11, 2019
P=N/A, N=44, Completed, Sponsor: University Hospital, Limoges
Active, not recruiting --> Completed | N=20 --> 13 | Trial completion date: Jun 2019 --> Jan 2018 Recruiting --> Completed
- | Trial completion, Enrollment change: Remission Induction and Sustenance in Graves' Disease 2 (clinicaltrials.gov) - Jan 10, 2019
P=N/A, N=139, Completed, Sponsor: Aalborg Universitetshospital
Recruiting --> Completed Active, not recruiting --> Completed | N=250 --> 139
- ||| Remicade (infliximab) / J&J
Trial completion: HARIR: Tracking Biologics Along the Silk Road (clinicaltrials.gov) - Jan 10, 2019
P=N/A, N=140, Completed, Sponsor: Janssen Pharmaceutica N.V., Belgium
Active, not recruiting --> Completed | N=250 --> 139 Active, not recruiting --> Completed
- | Enrollment change, Trial withdrawal: Gender Solutions Natural Knee Post-Market Study (clinicaltrials.gov) - Jan 10, 2019
P=N/A, N=0, Withdrawn, Sponsor: Zimmer Biomet
Active, not recruiting --> Completed N=300 --> 0 | Suspended --> Withdrawn
- | dimethyl fumarate / Generic mfg.
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: SURV-SEP: Monitoring of Patients Followed for a Multiple Sclerosis and Treated by Dimethyl-fumarate (clinicaltrials.gov) - Jan 9, 2019
P4, N=11, Terminated, Sponsor: Fondation Ophtalmologique Adolphe de Rothschild
N=300 --> 0 | Suspended --> Withdrawn N=250 --> 11 | Trial completion date: Aug 2023 --> Oct 2017 | Recruiting --> Terminated | Trial primary completion date: Aug 2019 --> Oct 2017; Another surveillance protocol was initiated by the OFSEP (OFSEP cohort) which allows to follow all the patients, whatever their treatment.
- ||| Actemra IV (tocilizumab) / Roche, JW Pharma
Trial completion: Tocihelper: Characterization of the Effect of Tocilizumab in Vivo and in Vitro on T Follicular Helper Cells in Rheumatoid Arthritis Patients and Consequence on B Cells Maturation (clinicaltrials.gov) - Jan 9, 2019
P=N/A, N=60, Completed, Sponsor: Association Aquitaine de Recherche Clinique en Rhumatologie
N=250 --> 11 | Trial completion date: Aug 2023 --> Oct 2017 | Recruiting --> Terminated | Trial primary completion date: Aug 2019 --> Oct 2017; Another surveillance protocol was initiated by the OFSEP (OFSEP cohort) which allows to follow all the patients, whatever their treatment. Recruiting --> Completed
- | Symlin (pramlintide) / AstraZeneca
Enrollment change: Efficacy of Pramlintide on Prevention of Weight Gain Early Onset of Type 1 Diabetes (clinicaltrials.gov) - Jan 8, 2019
P4, N=0, Withdrawn, Sponsor: University of Texas Southwestern Medical Center
Recruiting --> Completed N=24 --> 0
- ||| Trial completion, Phase classification, Enrollment change: Total Knee Arthroplasty (TKA) Cemented Versus Cementless Tibial Prosthesis Study (clinicaltrials.gov) - Jan 8, 2019
P=N/A, N=106, Completed, Sponsor: Washington University School of Medicine
N=24 --> 0 Active, not recruiting --> Completed | Phase classification: P2/3 --> PN/A | N=250 --> 106
- | Trial completion date, Trial primary completion date: Resistance Exercise in Rheumatic Disease (clinicaltrials.gov) - Jan 5, 2019
P=N/A, N=10, Suspended, Sponsor: Johns Hopkins University
Active, not recruiting --> Completed | Phase classification: P2/3 --> PN/A | N=250 --> 106 Trial completion date: Dec 2018 --> Jun 2019 | Trial primary completion date: Dec 2018 --> Jun 2019
- ||| Tysabri (natalizumab) / Biogen, Royalty
Trial completion, Trial completion date, Trial primary completion date: Clinical Disease Activity With Long Term Natalizumab Treatment (clinicaltrials.gov) - Jan 4, 2019
P=N/A, N=277, Completed, Sponsor: Biogen
Trial completion date: Dec 2018 --> Jun 2019 | Trial primary completion date: Dec 2018 --> Jun 2019 Active, not recruiting --> Completed | Trial completion date: Oct 2018 --> Aug 2016 | Trial primary completion date: Oct 2018 --> Aug 2016